When Treatment Is Mitigated by Adverse Events- The Economic Impact of Treatment-Associated Adverse Events in Cirrhotic Non-Responders Treated with Boceprevir or Telaprevir and Peginterferon Alpha/Ribavirin
Abstract
Authors
S. Sullivan C. McDermott D. Dieterich V. Martel-Laferriere S. Saab S. Gordon